Therapeutic potential of bone marrow-derived mesenchymal stem cells in formed aortic aneurysms of a mouse model

European Journal of Cardio-thoracic Surgery

Volumn 45, Issue 5, 2014, Pages

  Yamawaki ogata, Aika ^a   Fu, Xianming ^a   Hashizume, Ryotaro ^b   Fujimoto, Kazuro L ^a   Araki, Yoshimori ^a   Oshima, Hideki ^a   Narita, Yuji ^a   Usui, Akihiko ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aortic aneurysm; Bone marrow derived mesenchymal stem cells; Elastin; Intravenous injection; Macrophage; Matrix metalloproteinases

Indexed keywords

ANGIOTENSIN II; APOLIPOPROTEIN E; ELASTIN; GELATINASE A; GELATINASE B; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; SODIUM CHLORIDE; SOMATOMEDIN C; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; AORTA ANEURYSM; ARTICLE; BONE MARROW CELL; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL INFILTRATION; CLINICAL EFFECTIVENESS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HISTOPATHOLOGY; INTRAVENOUS ADMINISTRATION; MACROPHAGE FUNCTION; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; UPREGULATION; ANIMAL; AORTIC ANEURYSM; BONE MARROW TRANSPLANTATION; DISEASE MODEL; INTRAVENOUS DRUG ADMINISTRATION; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ADMINISTRATION, INTRAVENOUS; ANIMALS; AORTA; AORTIC ANEURYSM; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; ELASTIN; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MICE, TRANSGENIC;

EID: 84898614459     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezu018     Document Type: Article

References (24)

1. De Bruin JL, Baas AF, Buth J, Prinssen M, Verhoeven EL, Cuypers PW et al. Long-term outcome of open or endovascular repair of abdominal aortic aneurysm. N Engl J Med 2010;362:1881-9.
2. Smith D, Deveauxt T, Dillard C, Dinsmore M, Fitzgerald K, Flood A et al. 2009 clinical practice guideline for patients undergoing endovascular repair of abdominal aortic aneurysms (AAA). J Vasc Nurs 2009;27:48-63.
3. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002;110:625-32.
4. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009;78:539-52.
5. Nee L, Tuite N, Ryan MP, McMorrow T. TNF-alpha and IL-1 beta-mediated regulation of MMP-9 and TIMP-1 in human glomerular mesangial cells. Nephron Exp Nephrol 2007;107:e73-86.
6. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004;95:858-66.
7. Ozawa K, Sato K, Oh I, Ozaki K, Uchibori R, Obara Y et al. Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun 2008;30: 121-7.
8. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004;94:678-85.
9. Foster J, Rich CB, Florini JR. Insulin-like growth factor I, somatomedin C, induces the synthesis of tropoelastin in aortic tissue. Coll Relat Res 1987;7: 161-9.
10. Hashizume R, Yamawaki-Ogata A, Ueda Y, Wagner WR, Narita Y. Mesenchymal stem cells attenuate angiotensin II-induced aortic aneurysm growth in apolipoprotein E-deficient mice. J Vasc Surg 2011;54: 1743-52.
11. Fu XM, Yamawaki-Ogata A, Oshima H, Ueda Y, Usui A, Narita Y. Intravenous administration of mesenchymal stem cells prevents angiotensin II-induced aortic aneurysm formation in apolipoprotein E-deficient mouse. J Transl Med 2013;11:175.
12. Sun S, Guo Z, Xiao X, Liu B, Liu X, Tang PH et al. Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. Stem Cells 2003;21:527-35.
13. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000;105:1605-12.
14. Jones JA, Beck C, Barbour JR, Zavadzkas JA, Mukherjee R, Spinale FG et al. Alterations in aortic cellular constituents during thoracic aortic aneurysm development: myofibroblast-mediated vascular remodeling. Am J Pathol 2009;175:1746-56.
15. Sharma AK, Lu G, Jester A, Johnston WF, Zhao Y, Hajzus VA et al. Experimental abdominal aortic aneurysm formation is mediated by IL-17 and attenuated by mesenchymal stem cell treatment. Circulation 2012; 126:S38-45.
16. Durand E, Fournier B, Couty L, Lemitre M, Achouh P, Julia P et al. Endoluminal gingival fibroblast transfer reduces the size of rabbit carotid aneurisms via elastin repair. Arterioscler Thromb Vasc Biol 2012;32: 1892-901.
17. Kang JW, Park KD, Choi Y, Baek DH, Cho WS, Choi M et al. Biodistribution and in vivo efficacy of genetically modified human mesenchymal stem cells systemically transplanted into a mouse bone fracture model. Arch Pharm Res 2013;36:1013-22.
18. Schneider F, Saucy F, de Blic R, Dai J, Mohand F, Rouard H et al. Bone marrow mesenchymal stem cells stabilize already-formed aortic aneurysms more efficiently than vascular smooth muscle cells in a rat model. Eur J Vasc Endovasc Surg 2013;45:666-72.
19. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2006;26:987-94.
20. Adutler-Lieber S, Ben-Mordechai T, Naftali-Shani N, Asher E, Loberman DRaanani E et al. Human macrophage regulation via interaction with cardiac adipose tissue-derived mesenchymal stromal cells. J Cardiovasc Pharmacol Ther 2013;18:78-86.
21. Middleton RK, Lloyd GM, Bown MJ, Cooper NJ, London NJ, Sayers RD. The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study. J Vasc Surg 2007;45:574-80.
22. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579-86.
23. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003;108:863-8.
24. Nagaya N, Fujii T, Iwase T, Ohgushi H, Itoh T, Uematsu M et al. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Physiol Heart Circ Physiol 2004;287:H2670-6.